Thermo Fisher Scientific Inc. $TMO Shares Sold by PGGM Investments

Posted by Brian Himes on May 26th, 2026

PGGM Investments reduced its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) by 11.6% in the 4th quarter, Holdings Channel reports. The institutional investor owned 346,371 shares of the medical research company’s stock after selling 45,549 shares during the quarter. Thermo Fisher Scientific accounts for about 3.2% of PGGM Investments’ investment portfolio, making the stock its 4th biggest holding. PGGM Investments’ holdings in Thermo Fisher Scientific were worth $200,705,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently modified their holdings of TMO. Wellington Management Group LLP boosted its position in shares of Thermo Fisher Scientific by 88.9% during the third quarter. Wellington Management Group LLP now owns 2,699,460 shares of the medical research company’s stock worth $1,309,292,000 after buying an additional 1,270,191 shares during the period. Bank of New York Mellon Corp raised its holdings in Thermo Fisher Scientific by 54.7% during the third quarter. Bank of New York Mellon Corp now owns 3,571,857 shares of the medical research company’s stock worth $1,732,422,000 after acquiring an additional 1,262,967 shares in the last quarter. Franklin Resources Inc. raised its holdings in Thermo Fisher Scientific by 21.0% during the third quarter. Franklin Resources Inc. now owns 5,925,671 shares of the medical research company’s stock worth $2,874,069,000 after acquiring an additional 1,028,125 shares in the last quarter. Corient Private Wealth LLC raised its holdings in Thermo Fisher Scientific by 89.1% during the second quarter. Corient Private Wealth LLC now owns 1,752,607 shares of the medical research company’s stock worth $720,576,000 after acquiring an additional 825,649 shares in the last quarter. Finally, Capital World Investors raised its holdings in Thermo Fisher Scientific by 7.4% during the third quarter. Capital World Investors now owns 10,285,145 shares of the medical research company’s stock worth $4,988,132,000 after acquiring an additional 706,572 shares in the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. Morgan Stanley reiterated an “overweight” rating and set a $620.00 target price on shares of Thermo Fisher Scientific in a report on Monday, April 27th. Jefferies Financial Group upgraded Thermo Fisher Scientific to a “strong-buy” rating in a report on Friday, April 24th. Wall Street Zen lowered Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. Barclays dropped their target price on Thermo Fisher Scientific from $650.00 to $625.00 and set an “overweight” rating on the stock in a report on Tuesday, April 14th. Finally, UBS Group restated a “neutral” rating and issued a $615.00 price objective on shares of Thermo Fisher Scientific in a research note on Friday, January 30th. Two research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and three have assigned a Hold rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $616.10.

Read Our Latest Report on Thermo Fisher Scientific

Thermo Fisher Scientific Price Performance

NYSE:TMO opened at $448.55 on Tuesday. The company has a quick ratio of 1.15, a current ratio of 1.53 and a debt-to-equity ratio of 0.77. The stock’s 50 day moving average price is $479.71 and its two-hundred day moving average price is $537.15. The firm has a market capitalization of $166.69 billion, a price-to-earnings ratio of 24.66, a P/E/G ratio of 1.98 and a beta of 0.88. Thermo Fisher Scientific Inc. has a 12-month low of $385.46 and a 12-month high of $643.99.

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last released its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.25 by $0.19. The firm had revenue of $11.01 billion for the quarter, compared to analyst estimates of $10.86 billion. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The business’s revenue for the quarter was up 6.2% compared to the same quarter last year. During the same quarter in the prior year, the company earned $5.15 earnings per share. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. On average, analysts anticipate that Thermo Fisher Scientific Inc. will post 24.86 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, July 15th. Stockholders of record on Monday, June 15th will be paid a dividend of $0.47 per share. The ex-dividend date is Monday, June 15th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.34%.

Insider Buying and Selling

In other news, CEO Marc N. Casper sold 5,000 shares of the stock in a transaction that occurred on Wednesday, March 4th. The stock was sold at an average price of $512.40, for a total transaction of $2,562,000.00. Following the transaction, the chief executive officer owned 123,925 shares in the company, valued at approximately $63,499,170. This trade represents a 3.88% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Gianluca Pettiti sold 400 shares of the stock in a transaction that occurred on Monday, April 27th. The stock was sold at an average price of $462.66, for a total value of $185,064.00. Following the transaction, the chief operating officer owned 25,051 shares in the company, valued at approximately $11,590,095.66. This trade represents a 1.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is currently owned by company insiders.

Thermo Fisher Scientific Profile

(Free Report)

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.